A preclinical HDAC inhibitor showed potential to cause NK-dependent killing of the tumor cells, showing the NK-mediated antitumor effect of shHDAC6, though this model was not related to NKG2DL activity (Liu et al., 2018). Here, HDAC9 is linked to neoplasm.